2026年11月4日星期三
M
Meridian Globe
ព័ត៌មានបន្ទាន់
US experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

ប្រភព 柳叶刀 Lancet10 ថ្ងៃមុន
Summary

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

យើងផ្តល់តែសន្ទស្សន៍ចំណងជើង និងសេចក្តីសង្ខេប។ ខ្លឹមសារពេញលេញ និងសិទ្ធិអ្នកនិពន្ធ ជាកម្មសិទ្ធិរបស់ប្រភពដើម — សូមចុចតំណដើមដើម្បីអាន។

បើកឯកសារដើម
ផ្នែកព័ត៌មាន
Health
តំបន់
United Kingdom
Language
English
Item ID
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Meridian Globe